Incyte

Diversified biopharma

INCY · Nasdaq · United States

Share price · INCY

$117.80-5.67 (-4.59%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INCY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026+3.1%
  2. 22 Oct 2026+3.1%
  3. 30 Jul 2026-3.2%
  4. 28 Jul 2026+9.3%
  5. 15 Jun 2026-6.0%
  6. 3 Jun 2026+6.2%
  7. 30 Apr 2026-3.9%
  8. 10 Feb 2026-8.2%
  9. 8 Dec 2025-5.7%

Share of unusual movement by asset

For each asset, the share of INCY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tafasitamab
events and moves
7shown from 8 days
Retifanlimab
events and moves
6shown from 8 days
Ruxolitinib (Jakafi) (Jakafi)
events and moves
5shown from 8 days
baricitinib (Olumiant)
events and moves
5shown from 8 days
Axatilimab
events and moves
3shown from 8 days
Ruxolitinib (Opzelura) (Opzelura)
events and moves
3shown from 8 days
INCA33890
events and moves
1shown from 8 days
INCB161734
events and moves
1shown from 8 days
INCA033989
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—11%
Other company news (earnings, financing, releases naming no asset)—30%
Sessions with no dated event—59%

Assets

(13 total)
13Total Assets
9Approved
4Phase 3 / Filed
0Phase 1–2 / Early
23Diseases
Quick filter:
Showing 13 of 13 assets
Target & Modality
Approved
CSF-1RMonoclonal antibody
Graft-versus-Host Disease
Chronic Graft-versus-Host Disease
baricitinib(Olumiant)
Approved
JAK · JAK1/2Small molecule
Atopic DermatitisRheumatoid ArthritisAlopecia AreataCOVID-19
Approved
METSmall molecule
Non-Small Cell Lung Cancer
Pemigatinib(Pemazyre)
Approved
FGFR1/2/3Small molecule
Non-Small Cell Lung CancerBiliary Tract Cancer
Cholangiocarcinoma
Ponatinib(ICLUSIG)
Approved
BCR-ABL (including T315I)Small molecule
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerMerkel Cell CarcinomaAnal Cancer
Squamous Cell Carcinoma of the Anal Canal
Approved
JAK1/2Small molecule
MyelofibrosisPolycythemia VeraGraft-versus-Host Disease
Chronic Graft-versus-Host Disease
Approved
JAK1/2Small molecule
Atopic DermatitisPrurigo NodularisVitiligoHidradenitis Suppurativa
Approved
CD19Monoclonal antibody
Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma
Large B-Cell Lymphoma
Phase 3
mutant calreticulin (mutCALR)Monoclonal antibody
Essential Thrombocythemia
Phase 3
TGF-βR2 and PD-1 (conditional bispecific)Multispecific antibody
Non-Small Cell Lung CancerColorectal Cancer
Phase 3
CDK2Small molecule
Ovarian Cancer
Phase 3
KRAS G12DSmall molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Upcoming events

(26 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (9)
January 2027 (1)
AxatilimabPhase 1/2Chronic Graft-versus-host-disease
Est. primary completion 2027-01-06 · NCT06843408 · CT.gov ↗
What to watch
April 2027 (2)
INCB123667Phase 2Ovarian Cancer
Est. primary completion 2027-04-27 · NCT07023627 · CT.gov ↗
What to watch
Ruxolitinib (Opzelura)Phase 3NonSegmental Vitiligo
Est. primary completion 2027-04-30 · NCT06804811 · CT.gov ↗
What to watch
July 2027 (1)
CapmatinibPhase 2Advanced Solid Tumors Which Are cMET-dependent
Est. primary completion 2027-07-30 · NCT03040973 · CT.gov ↗
What to watch
August 2027 (1)
TafasitamabPhase 2Hematologic Malignancies
Est. primary completion 2027-08-29 · NCT06465433 · CT.gov ↗
What to watch
September 2027 (3)
TafasitamabPhase 2Immune Thrombocytopenia
Est. primary completion 2027-09-23 · NCT07104565 · CT.gov ↗
What to watch
AxatilimabPhase 3Chronic Graft-versus-host-disease
Est. primary completion 2027-09-28 · NCT06585774 · CT.gov ↗
What to watch
Ruxolitinib (Jakafi)Phase 2Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
Est. primary completion 2027-09-30 · NCT02955940 · CT.gov ↗
What to watch
October 2027 (1)
INCB123667Phase 3Ovarian Cancer
Est. primary completion 2027-10-12 · NCT07214779 · CT.gov ↗
What to watch
2028 (8)
February 2028 (1)
Ponatinib · ICLUSIGPhase 1/2Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia …
Est. primary completion 2028-02-01 · NCT03934372 · CT.gov ↗
What to watch
March 2028 (1)
baricitinib · OlumiantPhase 3Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Est. primary completion 2028-03 · NCT05723198 · CT.gov ↗
What to watch
May 2028 (1)
AxatilimabPhase 3Chronic Graft-versus-host-disease
Est. primary completion 2028-05-31 · NCT06821542 · CT.gov ↗
What to watch
June 2028 (1)
Ruxolitinib (Opzelura)Phase 3NonSegmental Vitiligo
Est. primary completion 2028-06-05 · NCT06548360 · CT.gov ↗
What to watch
July 2028 (1)
baricitinib · OlumiantPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2028-07 · NCT07222332 · CT.gov ↗
What to watch
September 2028 (2)
TafasitamabPhase 3DLBCL
Est. primary completion 2028-09 · NCT06521255 · CT.gov ↗
What to watch
INCB161734Phase 3Solid Tumors
Est. primary completion 2028-09-15 · NCT07522073 · CT.gov ↗
What to watch
December 2028 (1)
INCA33890Phase 3CRC (Colorectal Cancer)
Est. primary completion 2028-12-29 · NCT07284849 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
AxatilimabPhase 2Chronic Graft-versus-host-disease
Est. primary completion 2029-01-31 · NCT07124078 · CT.gov ↗
What to watch
May 2029 (1)
INCA33890Phase 2CRC (Colorectal Cancer)
Est. primary completion 2029-05-14 · NCT07823322 · CT.gov ↗
What to watch
June 2029 (1)
INCA033989Phase 3Essential Thrombocythemia
Est. primary completion 2029-06-15 · NCT07623200 · CT.gov ↗
What to watch
December 2029 (1)
Ruxolitinib (Jakafi)Phase 3Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Est. primary completion 2029-12-31 · NCT06401356 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Ruxolitinib (Jakafi)Phase 3Graft-versus-host Disease (GVHD)
Est. primary completion 2031-01-17 · NCT06615050 · CT.gov ↗
What to watch
February 2031 (1)
Pemigatinib · PemazyrePhase 2Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
Est. primary completion 2031-02-25 · NCT07862998 · CT.gov ↗
What to watch
July 2031 (2)
baricitinib · OlumiantPhase 3Juvenile Idiopathic Arthritis
Est. primary completion 2031-07 · NCT03773965 · CT.gov ↗
What to watch
baricitinib · OlumiantPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2031-07 · NCT07222137 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
INCB123667Phase 3Ovarian Cancer
Est. primary completion 2032-05-01 · NCT07797283 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(11)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 October 2026Topline resultAxatilimabMAXPIRe Phase 2 in IPF missed its primary endpoint
Syndax Pharmaceuticals · Source ↗
25 September 2026ApprovalbaricitinibFDA approves Olumiant for adolescents with severe alopecia areata
US, FDA · Eli Lilly and Company · Source ↗
29 July 2026ApprovalRuxolitinib (Opzelura)European Commission approves Opzelura cream for moderate atopic dermatitis
EU, EC · Source ↗
19 June 2026ApprovalTafasitamabJapan approval of Minjuvi with lenalidomide for relapsed/refractory DLBCL
JP, MHLW · Source ↗
2 June 2026Topline resultRuxolitinib (Jakafi)SENTRY Phase 3 topline results were mixed
7 May 2026Topline resultRuxolitinib (Jakafi)TRuE-AD4 24-week final data for Opzelura cream
7 May 2026Topline resultRuxolitinib (Opzelura)TRuE-AD4 final 24-week data for Opzelura cream
1 May 2026ApprovalRuxolitinib (Jakafi)FDA approves Jakafi XR (ruxolitinib) extended-release tablets
US, FDA · Source ↗
6 March 2026ApprovalRetifanlimabEuropean Commission approves Zynyz for advanced SCAC
EU, EC · Source ↗
27 February 2026Filing submittedbaricitinibOlumiant US submission for adolescent severe alopecia areata
US, FDA · Source ↗
5 January 2026Topline resultTafasitamabPhase 3 frontMIND of tafasitamab plus lenalidomide and R-CHOP met its primary endpoint
Incyte · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.6B$1.8B$3.3B+ $579M short-term inv.$785M-$675M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.7B$517M$4.0B+ $553M short-term inv.—$508M operating cash flowreport ↗
2026-Q1$1.3B$516M$4.0B+ $555M short-term inv.—$369M operating cash flowreport ↗
2025-Q3$1.4B$507M$2.5B+ $475M short-term inv.—$559M operating cash flowreport ↗
2025-Q2$1.2B$495M$2.0B+ $467M short-term inv.—$45M operating cash flowreport ↗
2025-Q1$1.1B$437M$1.9B+ $467M short-term inv.—$266M operating cash flowreport ↗
2024-Q3$1.1B$573M$1.3B+ $467M short-term inv.—$311M operating cash flowreport ↗
2024-Q2$1.0B$1.1B$989M+ $462M short-term inv.$445M-$576M operating cash flowreport ↗
2024-Q1$881M$429M$3.3B+ $504M short-term inv.—$219M operating cash flowreport ↗
2023-Q3$919M$376M$3.2B+ $289M short-term inv.—$148M operating cash flowreport ↗
2023-Q2$955M$401M$3.1B+ $292M short-term inv.—$307M operating cash flowreport ↗
2023-Q1$809M$407M$2.8B+ $292M short-term inv.—-$106M operating cash flowreport ↗
2022-Q3$823M$384M$2.7B+ $287M short-term inv.—$296M operating cash flowreport ↗
2022-Q2$911M$347M$2.4B+ $287M short-term inv.—$174M operating cash flowreport ↗
2022-Q1$733M$353M$2.3B+ $287M short-term inv.—$216M operating cash flowreport ↗
2021-Q3$813M$335M$2.0B+ $285M short-term inv.—$255M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$5.1B$2.1B$3.1B+ $483M short-term inv.—$1.4B operating cash flowreport ↗

Incyte reported full-year 2025 revenue of $5,141.24M, up 21.2% YoY, with R&D spend of $2,050.15M, down 21.4% YoY. Cash and equivalents were $3,099.67M, and the company recorded net income of $1,286.65M.

During the year, NIKTIMVO’s U.S. commercial launch commenced in January 2025 following its chronic GVHD approval, and MONJUVI/MINJUVI received approvals for relapsed/refractory follicular lymphoma in the U.S., EU, and Japan. The company submitted a response to the JAKAFI XR complete response letter and expects a regulatory decision and potential launch in mid-2026, while INCA033989 received FDA Breakthrough Therapy designation in essential thrombocythemia with Phase 3 initiation anticipated in mid-2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$4.2B$2.6B$1.7B+ $470M short-term inv.—$335M operating cash flowreport ↗
2023-FY$3.7B$1.6B$3.2B+ $443M short-term inv.—$496M operating cash flowreport ↗
2022-FY$3.4B$1.6B$3.0B+ $288M short-term inv.—$970M operating cash flowreport ↗
2021-FY$3.0B$1.5B$2.1B+ $291M short-term inv.—$749M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 56 sales ($67.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16CAGNONI PABLO J · President, Global Head of R&DOption exercise455$61.18$28KForm 4
2026-11-16Stein Steven H · CMO & Head of Late-Stage Dev.Option exercise576$68.25$39KForm 4
2026-11-16CAGNONI PABLO J · President, Global Head of R&DOption exercise422$61.76$26KForm 4
2026-11-16Stein Steven H · CMO & Head of Late-Stage Dev.Open-market sale576$121.98$70KForm 4
2026-11-16CAGNONI PABLO J · President, Global Head of R&DOption exercise926$64.25$59KForm 4
2026-11-16Stein Steven H · CMO & Head of Late-Stage Dev.Option exercise (derivative)576——Form 4
2026-11-16CAGNONI PABLO J · President, Global Head of R&DOption exercise839$71.93$60KForm 4
2026-11-16CAGNONI PABLO J · President, Global Head of R&DOpen-market sale877$121.98$107KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 804 reporting institutions held 202.0M shares ($18.2B, 99.1% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP30,744,412$2.9B
2BlackRock, Inc.18,978,198$1.8B
3Dodge & Cox12,252,356$1.2B
4VANGUARD CAPITAL MANAGEMENT LLC10,930,066$1.0B
5STATE STREET CORP9,641,384$907.4M
6VANGUARD PORTFOLIO MANAGEMENT LLC7,759,183$730.3M
7AQR CAPITAL MANAGEMENT LLC5,807,930$536.1M
8GEODE CAPITAL MANAGEMENT, LLC4,703,184$441.1M
9Invesco Ltd.3,870,764$364.3M
10RENAISSANCE TECHNOLOGIES LLC3,651,532$343.7M
11WELLINGTON MANAGEMENT GROUP LLP3,266,136$307.4M
12MORGAN STANLEY2,850,328$268.3M
13ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2,830,799$266.4M
14Robeco Institutional Asset Management B.V.2,514,383$236.7M
15GOLDMAN SACHS GROUP INC2,351,221$221.3M